Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Use of patient simulators to characterize the repeatability and reproducibility of automated oscillometric blood pressure monitors.

Sarhrani EM, Gilmore TB, Lamontagne AS, Harris LB, Kellett JS, Sweeney MP, Navas TI, Vesnovsky O, Ho C, Herbertson LH.

Blood Press Monit. 2018 May 16. doi: 10.1097/MBP.0000000000000329. [Epub ahead of print]

PMID:
29771693
2.

Effective implementation of novel MET pharmacodynamic assays in translational studies.

Srivastava AK, Navas T, Herrick WG, Hollingshead MG, Bottaro DP, Doroshow JH, Parchment RE.

Ann Transl Med. 2017 Jan;5(1):3. doi: 10.21037/atm.2016.12.78. Review.

3.

Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays.

Srivastava AK, Hollingshead MG, Weiner J, Navas T, Evrard YA, Khin SA, Ji JJ, Zhang Y, Borgel S, Pfister TD, Kinders RJ, Bottaro DP, Linehan WM, Tomaszewski JE, Doroshow JH, Parchment RE.

Clin Cancer Res. 2016 Jul 15;22(14):3683-94. doi: 10.1158/1078-0432.CCR-15-2323. Epub 2016 Mar 21.

4.

p38alpha-selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma.

Medicherla S, Reddy M, Ying J, Navas TA, Li L, Nguyen AN, Kerr I, Hanjarappa N, Protter AA, Higgins LS.

Anticancer Res. 2008 Nov-Dec;28(6A):3827-33.

5.

[Pneumocystosis in Venezuelan patients: epidemiology and diagnosis (2001-2006)].

Panizo MM, Reviákina V, Navas T, Casanova K, Sáez A, Guevara RN, Cáceres AM, Vera R, Sucre C, Arbona E.

Rev Iberoam Micol. 2008 Dec 31;25(4):226-31. Spanish.

6.

Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment.

Navas T, Zhou L, Estes M, Haghnazari E, Nguyen AN, Mo Y, Pahanish P, Mohindru M, Cao T, Higgins LS, Platanias LC, List A, Verma A, Bhagat T, Gajavelli S, Kambhampati S.

Leuk Lymphoma. 2008 Oct;49(10):1963-75. doi: 10.1080/10428190802322919. Erratum in: Leuk Lymphoma. 2009 Sep;50(9):1554. Bhagat, T [added]; Gajavelli, S [added]; Kambhampati, S [added].

7.

Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS.

Zhou L, Nguyen AN, Sohal D, Ying Ma J, Pahanish P, Gundabolu K, Hayman J, Chubak A, Mo Y, Bhagat TD, Das B, Kapoun AM, Navas TA, Parmar S, Kambhampati S, Pellagatti A, Braunchweig I, Zhang Y, Wickrema A, Medicherla S, Boultwood J, Platanias LC, Higgins LS, List AF, Bitzer M, Verma A.

Blood. 2008 Oct 15;112(8):3434-43. doi: 10.1182/blood-2008-02-139824. Epub 2008 May 12.

8.

Human leukocyte antigen class I and MICA haplotypes in a multicase family with Cladophialophora carrionii chromoblastomycosis.

Naranjo F, Márquez I, Gendzekhadze K, Zhang S, Fernández-Mestre M, Yegres F, Richard-Yegres N, Navas T, Montagnani S, Ogando V, Layrisse Z.

Tissue Antigens. 2006 Oct;68(4):287-92.

PMID:
17026462
9.

Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors.

Navas TA, Mohindru M, Estes M, Ma JY, Sokol L, Pahanish P, Parmar S, Haghnazari E, Zhou L, Collins R, Kerr I, Nguyen AN, Xu Y, Platanias LC, List AA, Higgins LS, Verma A.

Blood. 2006 Dec 15;108(13):4170-7. Epub 2006 Aug 29.

10.

Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.

Navas TA, Nguyen AN, Hideshima T, Reddy M, Ma JY, Haghnazari E, Henson M, Stebbins EG, Kerr I, O'Young G, Kapoun AM, Chakravarty S, Mavunkel B, Perumattam J, Luedtke G, Dugar S, Medicherla S, Protter AA, Schreiner GF, Anderson KC, Higgins LS.

Leukemia. 2006 Jun;20(6):1017-27.

PMID:
16617327
11.

Preventive and therapeutic potential of p38 alpha-selective mitogen-activated protein kinase inhibitor in nonobese diabetic mice with type 1 diabetes.

Medicherla S, Protter AA, Ma JY, Mangadu R, Almirez R, Koppelman B, Kerr I, Navas TA, Movius F, Reddy M, Liu YW, Luedtke G, Perumattam J, Mavunkel B, Dugar S, Schreiner GF.

J Pharmacol Exp Ther. 2006 Jul;318(1):99-107. Epub 2006 Apr 7.

12.

Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.

Nguyen AN, Stebbins EG, Henson M, O'Young G, Choi SJ, Quon D, Damm D, Reddy M, Ma JY, Haghnazari E, Kapoun AM, Medicherla S, Protter A, Schreiner GF, Kurihara N, Anderson J, Roodman GD, Navas TA, Higgins LS.

Exp Cell Res. 2006 Jun 10;312(10):1909-23. Epub 2006 Apr 4.

PMID:
16600214
13.

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.

Hideshima T, Podar K, Chauhan D, Ishitsuka K, Mitsiades C, Tai YT, Hamasaki M, Raje N, Hideshima H, Schreiner G, Nguyen AN, Navas T, Munshi NC, Richardson PG, Higgins LS, Anderson KC.

Oncogene. 2004 Nov 18;23(54):8766-76.

PMID:
15480425
14.

APC-independent activation of NK cells by the Toll-like receptor 3 agonist double-stranded RNA.

Schmidt KN, Leung B, Kwong M, Zarember KA, Satyal S, Navas TA, Wang F, Godowski PJ.

J Immunol. 2004 Jan 1;172(1):138-43.

15.

Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression.

Gewirtz AT, Navas TA, Lyons S, Godowski PJ, Madara JL.

J Immunol. 2001 Aug 15;167(4):1882-5.

16.

RIP2 is a Raf1-activated mitogen-activated protein kinase kinase.

Navas TA, Baldwin DT, Stewart TA.

J Biol Chem. 1999 Nov 19;274(47):33684-90.

17.

RIP3, a novel apoptosis-inducing kinase.

Sun X, Lee J, Navas T, Baldwin DT, Stewart TA, Dixit VM.

J Biol Chem. 1999 Jun 11;274(24):16871-5.

19.
20.

DNA damage and cell cycle regulation of ribonucleotide reductase.

Elledge SJ, Zhou Z, Allen JB, Navas TA.

Bioessays. 1993 May;15(5):333-9. Review.

PMID:
8343143

Supplemental Content

Support Center